Elevated D-dimer levels in African Americans with sickle cell trait

Blood

Volumn 127, Issue 18, 2016, Pages 2261-2263

  Naik, Rakhi P ^a   Wilson, James G ^b   Ekunwe, Lynette ^c   Mwasongwe, Stanford ^c   Duan, Qing ^d   Li, Yun ^d   Correa, Adolfo ^e   Reiner, Alexander P ^f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c JACKSON STATE UNIVERSITY   (United States)

^d University of North Carolina at Chapel Hill   (United States)

^e UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; D DIMER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; PADGEM PROTEIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; HEMOGLOBIN S;

AFRICAN AMERICAN; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; GENE SEQUENCE; HUMAN; INFORMED CONSENT; INSTITUTIONAL REVIEW; INVESTIGATIVE PROCEDURES; LETTER; LEUKOCYTE COUNT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SICKLE CELL TRAIT; SMOKING; THROMBOCYTE COUNT; ADULT; BLOOD; FEMALE; GENETICS; GENOTYPE; MALE; YOUNG ADULT;

ADULT; AFRICAN AMERICANS; COHORT STUDIES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; GENOTYPE; HEMOGLOBIN, SICKLE; HUMANS; MALE; SICKLE CELL TRAIT; YOUNG ADULT;

EID: 84969216965     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-01-694422     Document Type: Letter

References (22)

1. Ataga KI. Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica. 2009;94(11):1481-1484.
2. Naik RP, Streiff MB, Lanzkron S. Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis. 2013;35(3):352-358.
3. Chiu D, Lubin B, Roelofsen B, van Deenen LL. Sickled erythrocytes accelerate clotting in vitro: an effect of abnormal membrane lipid asymmetry. Blood. 1981; 58(2):398-401.
4. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood. 2007; 110(6):2166-2172.
5. Ataga KI, Brittain JE, Desai P, et al. Association of coagulation activation with clinical complications in sickle cell disease. PLoS One. 2012;7(1):e29786.
6. Hagger D, Wolff S, Owen J, Samson D. Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrinolysis. 1995;6(2):93-99.
7. Shah N, Thornburg C, Telen MJ, Ortel TL. Characterization of the hypercoagulable state in patients with sickle cell disease. Thromb Res. 2012;130(5):e241-e245.
8. Kanavaki I, Makrythanasis P, Lazaropoulou C, et al. Adhesion molecules and high-sensitivity C-reactive protein levels in patients with sickle cell betathalassaemia. Eur J Clin Invest. 2012;42(1):27-33.
9. Hatzipantelis ES, Pana ZD, Gombakis N, et al. Endothelial activation and inflammation biomarkers in children and adolescents with sickle cell disease. Int J Hematol. 2013;98(2):158-163.
10. Afshar-Kharghan V, Thiagarajan P. Leukocyte adhesion and thrombosis. Curr Opin Hematol. 2006;13(1):34-39.
11. Naik RP, Streiff MB, Haywood C Jr, Segal JB, Lanzkron S. Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease. J Thromb Haemost. 2014;12(12):2010-2016.
12. Naik RP, Streiff MB, Haywood C Jr, Nelson JA, Lanzkron S. Venous thromboembolism in adults with sickle cell disease: a serious and underrecognized complication. Am J Med. 2013;126(5):443-449.
13. Folsom AR, Tang W, Roetker NS, et al. Prospective study of sickle cell trait and venous thromboembolism incidence. J Thromb Haemost. 2015;13(1):2-9.
14. Austin H, Key NS, Benson JM, et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood. 2007;110(3):908-912.
15. Westerman MP, Green D, Gilman-Sachs A, et al. Coagulation changes in individuals with sickle cell trait. Am J Hematol. 2002;69(2):89-94.
16. Amin C, Adam S, Mooberry MJ, et al. Coagulation activation in sickle cell trait: an exploratory study. Br J Haematol. 2015;171(4):638-646.
17. Taylor HA Jr. The Jackson Heart Study: an overview. Ethn Dis. 2005;15(4 Suppl 6):S6-1-3.
18. Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014;311(11): 1117-1124.
19. Naik RP, Derebail VK, Grams ME, et al. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA. 2014; 312(20):2115-2125.
20. Karami-Djurabi R, Klok FA, Kooiman J, Velthuis SI, Nijkeuter M, Huisman MV. D-dimer testing in patients with suspected pulmonary embolism and impaired renal function. Am J Med. 2009;122(11):1050-1053.
21. Folsom AR, Alonso A, George KM, Roetker NS, Tang W, Cushman M. Prospective study of plasma D-dimer and incident venous thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Res. 2015; 136(4):781-785.
22. Gupta AK, Kirchner KA, Nicholson R, et al. Effects of alpha-thalassemia and sickle polymerization tendency on the urine-concentrating defect of individuals with sickle cell trait. J Clin Invest. 1991;88(6):1963-1968.